Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to 337.93%.

  • Autolus Therapeutics' EBIT Margin changed N/A to 337.93% in Q3 2025 from the same period last year, while for Sep 2025 it was 535.8%, marking a year-over-year increase of 16308700.0%. This contributed to the annual value of 2385.63% for FY2024, which is 81974700.0% up from last year.
  • Autolus Therapeutics' EBIT Margin amounted to 337.93% in Q3 2025.
  • In the past 5 years, Autolus Therapeutics' EBIT Margin registered a high of 292.58% during Q2 2025, and its lowest value of 261600.0% during Q4 2024.
  • Moreover, its 5-year median value for EBIT Margin was 2303.26% (2023), whereas its average is 27712.83%.
  • The largest annual percentage gain for Autolus Therapeutics' EBIT Margin in the last 5 years was 187687600bps (2023), contrasted with its biggest fall of -89912500bps (2023).
  • Quarter analysis of 5 years shows Autolus Therapeutics' EBIT Margin stood at 17099.58% in 2021, then skyrocketed by 98bps to 318.39% in 2022, then plummeted by -3219bps to 10567.73% in 2023, then crashed by -2375bps to 261600.0% in 2024, then skyrocketed by 100bps to 337.93% in 2025.
  • Its last three reported values are 337.93% in Q3 2025, 292.58% for Q2 2025, and 726.34% during Q1 2025.